Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke "NOR-TEST"


Phase 3 Results N/A

Summary of Purpose

BACKGROUND: Alteplase dissolves blood vessel clots in acute ischemic stroke and is the only approved acute drug treatment <4½ hours of stroke onset. The overall benefit from alteplase is substantial, but up to 2/3 of patients with large artery clots may not achieve reopening of the vessel and up to 40% of the patients may remain severely disabled or die, leaving substantial room for improvement. Tenecteplase,...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 5 May 2017.

1 Sep 2012 21 Sep 2013 31 Dec 2016 31 Dec 2016 1 May 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment


  • Lars Thomassen, MD PhD Prof +47 55 97 50 00

  • Nicola Logallo, MD PhD